ArticleFrontiers in cardiovascular medicine2019
Differences in microRNA-29 and Pro-fibrotic Gene Expression in Mouse and Human Hypertrophic Cardiomyopathy.
Open access · goldAbstract read
In one paragraph
Article in Frontiers in cardiovascular medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
3.2field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 44 citations in OpenAlex.
- Mutation specific impairment of fatty acid and pyruvate oxidation in hypertrophic cardiomyopathy mouse models.Journal of molecular and cellular cardiology · 2026Article
- MicroRNAs in Heart Failure Pathogenesis and Progression: Mechanistic Control, Biomarker Potential, and Translational Perspectives.Life (Basel, Switzerland) · 2026Review
- Nerolidol attenuates cardiac hypertrophy and fibrosis in mice: Modulation of collagen type I, apoptotic and endothelial gene expression.Iranian journal of basic medical sciences · 2026Article
- Atrial Fibrillation in Diabetes: Pathogenesis and Targeted Rhythm Control Strategies.Current issues in molecular biology · 2025Review
- Translation of pathophysiological mechanisms of atrial fibrosis into new diagnostic and therapeutic approaches.Nature reviews. Cardiology · 2025Review
- Experimental Models of Hypertrophic Cardiomyopathy: A Systematic Review.JACC. Basic to translational science · 2025Review
- MiR-133b-3p attenuates angiotensin II-induced cardiac hypertrophy through the inhibition of apoptosis by targetingActa biochimica et biophysica Sinica · 2025Article
- The Role of Signalling Pathways in Myocardial Fibrosis in Hypertrophic Cardiomyopathy.Reviews in cardiovascular medicine · 2025Review
- CRISPR/Cas9-mediated CH2 deletion of Fel d1 triggers transcriptomic reprogramming and disease-associated pathways in feline cells.Frontiers in cell and developmental biology · 2025Article
- Integrated Multi-omics Analysis of Hub Genes and miRNA Interactions in Hypertrophic Cardiomyopathy.Current genomics · 2025Article
- Non-coding RNAs in heart failure: epigenetic regulatory mechanisms and therapeutic potential.Frontiers in genetics · 2025Review
- Atrial Fibrosis in Atrial Fibrillation: Mechanistic Insights, Diagnostic Challenges, and Emerging Therapeutic Targets.International journal of molecular sciences · 2024Review
- Hypertrophic cardiomyopathy-associated mutations drive stromal activation via EGFR-mediated paracrine signaling.Science advances · 2024Article
- Proteome-wide Characterization and Pathophysiology Correlation in Non-ischemic Cardiomyopathies.Korean circulation journal · 2024Article
- Allele-specific dysregulation of lipid and energy metabolism in early-stage hypertrophic cardiomyopathy.Journal of molecular and cellular cardiology plus · 2024Article
- Single-nucleus RNA/ATAC-seq in early-stage HCM models predicts SWI/SNF-activation in mutant-myocytes, and allele-specific differences in fibroblasts.bioRxiv : the preprint server for biology · 2024Article
- The crucial relationship between miRNA-27 and CSE/HInternational journal of medical sciences · 2024Article
- Myocardial Fibrosis in Hypertrophic Cardiomyopathy: A Perspective from Fibroblasts.International journal of molecular sciences · 2023Review
- Circ-sh3rf3/GATA-4/miR-29a regulatory axis in fibroblast-myofibroblast differentiation and myocardial fibrosis.Cellular and molecular life sciences : CMLS · 2023Article
- Genetic Factors for Coronary Heart Disease and Their Mechanisms: A Meta-Analysis and Comprehensive Review of Common Variants from Genome-Wide Association Studies.Diagnostics (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 6 institutions in 1 country.
Yamin LiuDivision of Cardiology, Hypertrophic Cardiomyopathy Center of Excellence, University of California, San Francisco, San Francisco, CA, United States.
Junaid AfzalDivision of Cardiology, Hypertrophic Cardiomyopathy Center of Excellence, University of California, San Francisco, San Francisco, CA, United States.
Styliani VakrouHypertrophic Cardiomyopathy Center of Excellence, Johns Hopkins University, Baltimore, MD, United States.
Gabriela V GreenlandDivision of Cardiology, Hypertrophic Cardiomyopathy Center of Excellence, University of California, San Francisco, San Francisco, CA, United States.
C Conover TalbotJohns Hopkins School of Medicine, Institute for Basic Biomedical Sciences, Baltimore, MD, United States.
Virginia B HeblIntermountain Medical Center, Intermountain Heart Institute, Murray, UT, United States.
Yufan GuanHypertrophic Cardiomyopathy Center of Excellence, Johns Hopkins University, Baltimore, MD, United States.
Rehan KarmaliDivision of Cardiology, Hypertrophic Cardiomyopathy Center of Excellence, University of California, San Francisco, San Francisco, CA, United States.
Jil C TardiffSarver Heart Center, University of Arizona Health Sciences, Tucson, AZ, United States.
Leslie A LeinwandMolecular, Cellular and Developmental Biology, Biofrontiers Institute, University of Colorado, Boulder, CO, United States.
Jeffrey E OlginDivision of Cardiology, Hypertrophic Cardiomyopathy Center of Excellence, University of California, San Francisco, San Francisco, CA, United States.
Samarjit DasDepartment of Anesthesia and Critical Care Medicine, Johns Hopkins University, Baltimore, MD, United States.
Ryuya FukunagaDepartment of Biological Chemistry, Johns Hopkins School of Medicine, Baltimore, MD, United States.
M Roselle AbrahamDivision of Cardiology, Hypertrophic Cardiomyopathy Center of Excellence, University of California, San Francisco, San Francisco, CA, United States.
University of California, San Francisco · USJohns Hopkins University · USIntermountain Medical Center · USJohns Hopkins Medicine · USUniversity of Arizona · USUniversity of Colorado Boulder · US
Funding
MYOSIN GENE DIVERSITY AND FUNCTIONR01GM029090 · NIGMS · YESHIVA UNIVERSITY · PI Leslie Anne Leinwand · 1985 to 2026
$12.3MIntegrative Approach to Divergent Remodeling in Thin Filament CardiomyopathiesR01HL075619 · NHLBI · UNIVERSITY OF ARIZONA · PI TARDIFF, JIL C · 2004 to 2025
$8.6MMechanism to regulate the length of small silencing RNAsR01GM116841 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI FUKUNAGA, RYUYA · 2017 to 2021
$1.7MNHLBI NIH HHS R01 HL075619NIGMS NIH HHS R01 GM029090NIGMS NIH HHS R01 GM116841
Abstract
PubMed holds no abstract for this paper.
Indexed as
collagenhumanshypertrophic cardiomyopathymiR-29mouseTGF-beta
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.